Current Report Filing (8-k)
January 19 2022 - 3:14PM
Edgar (US Regulatory)
0000890821
false
0000890821
2022-01-18
2022-01-18
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): January 18, 2022
Enveric
Biosciences, Inc.
(Exact
name of Registrant as specified in its charter)
Delaware
|
|
001-38286
|
|
95-4484725
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
No.)
|
|
(IRS
Employer
Identification
No.)
|
Enveric
Biosciences, Inc.
4851
Tamiami Trail N, Suite 200
Naples,
FL 34103
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code: (239) 302-1707
N/A
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
stock, par value $0.01 per share
|
|
ENVB
|
|
The
Nasdaq Stock Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
7.01.
|
Regulation
FD Disclosure.
|
On
January 18, 2022, Enveric Biosciences, Inc. (the “Company”) issued a press release containing a letter from the
Company’s CEO providing a 2021 year in review and 2022 outlook. A copy of such press release is attached hereto as Exhibit
99.1 and is incorporated by reference herein.
In
accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, is being
furnished pursuant to Item 7.01 and shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act, or otherwise
subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or
the Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such a filing.
Item
9.01.
|
Financial
Statements and Exhibits.
|
(d)
Exhibits.
*
* *
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
ENVERIC
BIOSCIENCES, INC.
|
|
|
|
|
Date:
|
January
19, 2022
|
By:
|
/s/
Joseph Tucker
|
|
|
|
Joseph
Tucker
|
|
|
|
Chief
Executive Officer
|
Ameri (NASDAQ:AMRH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ameri (NASDAQ:AMRH)
Historical Stock Chart
From Apr 2023 to Apr 2024